Stockscreener 앱 받기
9.17
1.66%
0.15
시간 외 거래:
9.02
-0.15
-1.64%
Dyne Therapeutics Inc 주식(DYN)의 최신 뉴스
Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
What analysts say about Dyne Therapeutics Inc. stockTriple-digit return opportunities - Autocar Professional
Dyne Therapeutics Inc. Stock Analysis and ForecastGame-changing returns - PrintWeekIndia
What drives Dyne Therapeutics Inc. stock priceRapid return acceleration - jammulinksnews.com
Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey
Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus
Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha
Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN
Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - FinancialContent
Evercore ISI Analyst Lowers Dyne Therapeutics Price Target to $41, Maintains Outperform Rating - AInvest
RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT - Yahoo Finance
Dyne Therapeutics (DYN) Sees Price Target Reduced by Evercore IS - GuruFocus
Dyne Therapeutics’ DYNE-251 Study Update: A Potential Game-Changer for Duchenne Muscular Dystrophy - TipRanks
RBC Capital Sticks to Their Buy Rating for Dyne Therapeutics (DYN) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
(DYN) Trading Report - news.stocktradersdaily.com
Dyne Therapeutics, Inc. (DYN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ATTENTION DYN Shareholders: Lost Money on Dyne Therapeutics, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Dyne Therapeutics, Inc. (DYN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Petri Dish: ProFound’s Novartis deal worth $750M, Dyne secures debt - The Business Journals
Dyne Therapeutics Announces Closing of Public Offering of Common - GuruFocus
Dyne Therapeutics' $230M Capital Injection: A Strategic Gamble in Rare Neuromuscular Disorders? - AInvest
Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
Dyne Therapeutics Closes $230 Million Public Offering of Common Stock - Quiver Quantitative
Dyne Therapeutics Announces Closing of Public Offering of - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Dyne Therapeutics, Inc. (DYN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Dyne Therapeutics, Inc. (DYN) And Encourages Shareholders to Connect - ACCESS Newswire
Shareholders Alert: Investigation Into Dyne Therapeutics, Inc. (DYN)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Dyne Therapeutics (DYN) Launches $200 Million Public Offering - GuruFocus
Dyne Therapeutics slides on $200 mln equity raise - TradingView
Dyne Therapeutics, Inc. (DYN) Under Investigation for Potential Securities Law ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Dyne Therapeutics' $200M Stock Offering: Strategic Necessity or Shareholder Dilution? - AInvest
Fraud Investigation: Levi & Korsinsky Investigates Dyne Therapeutics, Inc. (DYN) on Behalf of Shareholders - ACCESS Newswire
Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - 富途牛牛
Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr - Nasdaq
Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital - citybiz
Dyne Therapeutics Announces Proposed Public Offering of Common S - GuruFocus
Dyne Therapeutics stock falls after announcing $200 million share offering By Investing.com - Investing.com South Africa
Dyne Therapeutics stock falls after announcing $200 million share offering - Investing.com
Dyne Therapeutics Secures Up to $275 Million in Debt Financing From Hercules Capital - 富途牛牛
Potential Securities Fraud: Levi & Korsinsky Investigates Dyne Therapeutics, Inc. (DYN) - ACCESS Newswire
Dyne Therapeutics Secures $275M Loan Agreement - TipRanks
JonesTrading Initiates Coverage on Dyne Therapeutics With Buy Rating, $30 Price Target - MarketScreener
Dyne Therapeutics (DYN) Receives Buy Rating with Strong Growth Potential | DYN Stock News - GuruFocus
(DYN) Investment Report - news.stocktradersdaily.com
0.87%
0.17%
자본화:
|
볼륨(24시간):